GeneDx Holdings Corp.
NASDAQ Global SelectTotal Valuation
GeneDx Holdings Corp. carries a market capitalization of 1.65B, placing it among publicly traded companies globally. Its enterprise value stands at -2.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.65B |
| Enterprise Value | -2.49M |
Share Statistics
GeneDx Holdings Corp. currently has 29.67M shares outstanding.
| Shares Outstanding | 29.67M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
GeneDx Holdings Corp. maintains a current ratio of 3.09, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 66.19, indicating elevated leverage, while an interest coverage ratio of -5.45 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.09 |
| Quick Ratio | 2.83 |
| Debt / Equity | 66.19 |
| Debt / EBITDA | -20.13 |
| Interest Coverage | -5.45 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -16.33 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 10.82 |
Taxes
| Income Tax | 334,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
GeneDx Holdings Corp.'s stock has declined approximately -98.6% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | -98.6% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.03 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -8.35M, while operating income came in at -34.71M.
| Revenue | 442.68M |
| Gross Profit | 307.91M |
| Operating Income | -34.71M |
| Pretax Income | -77.47M |
| Net Income | -77.81M |
| EBITDA | -8.35M |
| EBIT | -34.71M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
GeneDx Holdings Corp. holds 170.69M in cash and equivalents against 168.19M in total debt, resulting in a net debt position of 2.81M. Total book value stands at -1.44B, with working capital of 182.99M providing operational flexibility.
| Cash & Cash Equivalents | 170.69M |
| Total Debt | 168.19M |
| Net Debt | 2.81M |
| Equity (Book Value) | -1.44B |
| Book Value Per Share | N/A |
| Working Capital | 182.99M |
Cash Flow
GeneDx Holdings Corp. produced -9.31M in operating cash flow over the past twelve months.
| Operating Cash Flow | -9.31M |
| Capital Expenditures | -19.34M |
| Free Cash Flow | -28.65M |
| FCF Per Share | N/A |
Margins
GeneDx Holdings Corp. operates with a gross margin of 69.56, reflecting its pricing power and cost economics. The operating margin of -7.84 and net profit margin of -17.58 provide insight into operational efficiency.
| Gross Margin | 69.56 |
| Operating Margin | -7.84 |
| Pretax Margin | -17.50 |
| Profit Margin | -17.58 |
| EBITDA Margin | -1.89 |
Scores
GeneDx Holdings Corp. posts an Altman Z-Score of -4.07, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.07 |